Home
Clinical Trials
Efficacy Study of ABR-215050 ...

Efficacy Study of ABR-215050 to Treat Prostate Cancer

Last Updated: 2015-10-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

206 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate ABR-215050 as a possible treatment for prostate cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01503229

Hormone-Resistant Prostate Cancer Metastatic Prostate Carcinoma Recurrent Prostate Carcinoma +1 more

COMPLETED PHASE2

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

NCT01234311

Prostate Cancer

COMPLETED PHASE3

CCI-779 in Treating Patients With Prostate Cancer

NCT00012142

Prostate Cancer

COMPLETED PHASE2

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

NCT05204927

Metastasis From Malignant Tumor of Prostate

ACTIVE_NOT_RECRUITING PHASE3

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

NCT04262154

Metastatic Prostate Cancer

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For asymptomatic patients with Castrate-Resistant Prostate Cancer (CRPC), a "window of opportunity" is present. During this "window of opportunity" an intervention with little or no toxicity and the potential for extending the "symptom-free" period would be of great value to keep metastatic patients in an asymptomatic stage and thus delay the introduction of chemotherapy. The purpose of this study is to evaluate the safety and efficacy of ABR-215050 as an interventional agent for this role.

Overall survival for patients participating in study 07TASQ08 will be evaluated retrospectively using a separate study protocol 11TASQ11.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Group Type ACTIVE_COMPARATOR

ABR-215050, tasquinimod

Intervention Type DRUG

Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)

B

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Identical appearing gelatin capsules containing placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ABR-215050, tasquinimod

Intervention Type DRUG

Placebo

Identical appearing gelatin capsules containing placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed diagnosis of adenocarcinoma of the prostate
* Asymptomatic metastatic CRPC (VAS pain score less than or equal to 3). The patient may take non-opioid analgesics for non-cancer pain discomfort
* Evidence of metastatic disease from CT or Bone scan
* Evidence of progressive disease after castration levels of testosterone have been achieved defined by any of the following criteria:

* Increased serum prostate-specific antigen (PSA) levels (Confirmed by 3 consecutive PSA measurements within 1 year with at least 14 days between each measurement)
* Progression of bidimensionally measurable soft tissue (nodal) metastasis: (CT scan or MRI)
* Progression of bone disease: (New bone lesions by bone scan within the past 12 weeks)
* Castrate levels of serum testosterone (less than or equal to 50 ng/dL or 1.7 nmol/L. Testosterone levels will not be required for patients who have had bilateral orchiectomy)
* Karnofsky score 70-100
* Laboratory values as follows:

* Hb greater than or equal to 90g/L (greater than or equal to 9g/dL)
* Serum creatinine less than or equal to 1.5 x upper limit of normal (ULN)
* Total bilirubin less than or equal to 1.5 x ULN
* AST (SGOT) / ALT (SGPT) less than or equal to 2.5 x ULN
* Serum amylase less than or equal to ULN. (If serum amylase is greater than ULN, pancreatic amylase and serum lipase should be analyzed. If both pancreatic amylase and serum lipase is greater than ULN, exclude patient)
* Patient if sexually active with partner of child bearing potential will agree to use adequate contraceptive methods (barrier contraceptive with spermicide or vasectomy) while on study drug
* No evidence (greater than or equal to 5 years) of prior malignancies (except successfully treated basal cell, squamous cell carcinoma of the skin)
* Ability to administer and retain oral medication
* Able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria

* Prior cytotoxic chemotherapy within 3 years
* Previous anti-cancer therapy using biologics or vaccines within the last 6 months. Previous treatment with bevacizumab is not allowed.
* Any treatment modalities, involving radiation and surgery, not discontinued at least 4 weeks prior to treatment in this study
* Myocardial infarction or any acute coronary syndrome within one year or current uncontrolled arrhythmias, symptomatic uncontrolled congestive heart failure, unstable angina pectoris, uncontrolled hypertension
* History of pancreatitis
* Any condition, including the presence of laboratory abnormalities, which confounds the ability to interpret data from the study or places the patient at unacceptable risk if he participates in the study
* Concurrent use of other anti-cancer agents or treatments \[a stable dose of LHRH agonists, bicalutamide (e.g. Casodex) and/or other antiandrogens is allowed\]
* Known brain metastases
* Simultaneous participation in any other study involving investigational drugs or having participated in a study less than 4 weeks prior to start of study treatment
* Concomitant systemic treatment with warfarin and/or corticosteroids corresponding to a prednisolone dose above 5 mg/day
* Exposure to ketoconazole or other strong CYP3A4 inhibitors or inducers intravenously or orally within 14 days prior to inclusion
* Known positive serology for HIV (patients with known history of HIV will be excluded because of potential for unforeseen toxicity and morbidity in an immunocompromised host)
* Chronic hepatitis with advanced, decompensated hepatic disease or cirrhosis of the liver or history of a chronic virus hepatitis or known viral hepatitis carrier (patients recovered from hepatitis will be allowed to enter the study)

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Goran Forsberg, Assoc. Prof.

Role: STUDY_DIRECTOR

Active Biotech AB

Roberto Pili, MD

Role: PRINCIPAL_INVESTIGATOR

Roswell Park Cancer Institute, Buffalo, New York

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alaska Clinical Research Center LLC

Anchorage, Alaska, United States

Site Status

Southern California Permanente Medical Group

Anaheim, California, United States

Site Status

Southern California Permanente Medical Group

Baldwin Park, California, United States

Site Status

Southern California Permanente Medical Group

Bellflower, California, United States

Site Status

Pacific Clinical Center

Beverly Hills, California, United States

Site Status

South County Hematology/Oncology

Chula Vista, California, United States

Site Status

Southern California Permanente Medical Group

Fontana, California, United States

Site Status

Southern California Permanente Medical Group

Irvine, California, United States

Site Status

Cancer Center Oncology Medical Group

La Mesa, California, United States

Site Status

North County Oncology Medical Clinic, Inc.

Oceanside, California, United States

Site Status